Therapiemöglichkeiten der Depression nach Non-Response

Henrik Walter; Raoul Haaf; Stephan Köhler

doi:10.1055/a-2103-7920

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2023; 42(07/08): 419-429
DOI: 10.1055/a-2103-7920

Schwerpunkt

Therapiemöglichkeiten der Depression nach Non-Response

Ein Update für die PraxisTreatment strategies for depression after non-responseAn update for clinical practice

Henrik Walter

¹Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin

,

Raoul Haaf

¹Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin

,

Stephan Köhler

¹Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin

› Institutsangaben

Abstract

ZUSAMMENFASSUNG

Die unipolare Depression stellt eine der häufigsten psychiatrischen Erkrankungen dar. Ein beträchtlicher Prozentsatz der Menschen, die an einer Depression leiden, erfahren trotz leitliniengerechter Ersttherapie mittels moderner psychopharmakologischer und/oder psychotherapeutischer Verfahren keine ausreichende Linderung ihrer Symptome. Die Therapie von Patienten mit einer „therapieresistenten“ oder „schwer zu behandelnden“ Depression stellt daher eine häufige Herausforderung in der alltäglichen Praxis dar. Anders als der Terminus „therapieresistent“ suggeriert, existieren jedoch eine Vielzahl an evidenzbasierten Therapieoptionen, die bei unzureichendem Ansprechen auf eine Standardtherapie mit Antidepressivum und Psychotherapie eingesetzt werden können. Mittels selektiver Literaturrecherche und unter Bezugnahme auf die kürzlich veröffentlichte 3. Version der Deutschen S3-Leitlinie zur Depression gibt vorliegender Artikel einen Überblick über weitere Therapieoptionen sowie Basismaßnahmen jenseits der Standardtherapien der unipolaren Depression.

ABSTRACT

Unipolar depression is one of the most common psychiatric disorders. A substantial percentage of people suffering from depression do not experience sufficient relief of their symptoms despite guideline-compliant initial therapy using modern psychopharmacological and/or psychotherapeutic methods. The treatment of patients with “treatment-resistant” or “difficult-to-treat” depression is therefore a frequent challenge in everyday practice. However, contrary to what the term “treatment-resistant” suggests, a variety of evidence-based treatment options exist, that can be considered when responses to standard antidepressant- and psychotherapy are insufficient. By means of a selective literature search and with reference to the recently published third version of the German S3 guideline on depression, this article provides an overview of further therapy options as well as basic measures beyond standard therapies for unipolar depression.

Schlüsselwörter

Behandlungsresistente Depression - depressive Störung - Pharmakotherapie - Psychotherapie - Hirnstimulation - neue Therapien

Key words

Treatment-resistant depression - depressive disorder - pharmacotherapy - psychotherapy - brain stimulation - new therapies

Volltext

Referenzen

Literatur
1 Jacobi F, Höfler M, Strehle J. et al Psychische Störungen in der Allgemeinbevölkerung. Nervenarzt 2014; 85 (01) 77-87
2 Wittchen HU, Jacobi F, Rehm J. et al The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21 (09) 655-679
3 Moreno-Agostino D, Wu YT, Daskalopoulou C. et al Global trends in the prevalence and incidence of depression:a systematic review and meta-analysis. J Affect Disord 2021; 281: 235-243
4 Cipriani A, Furukawa TA, Salanti G. et al Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391 10128 1357-1366
5 Radisch J, Buchtemann D, Kastner D. et al A literature- and expert-based analysis of the outpatient treatment of depressive ill people in Germany Psychiatr Prax. 2013; 40 (05) 252-258
6 Cuijpers P, Karyotaki E, Ciharova M. et al The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand 2021; 144 (03) 288-299
7 BÄK K, AWMF. et al. S3-Leitlinie Nationale VersorgungsLeitlinie Unipolare Depression. 3.1. Retrieved 23.05.2023. www.leitlinien.de/themen/depression Stand: 1.6.2023
8 Bschor T, Bauer M, Adli M. Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int 2014; 111 (45) 766-775
9 Thase M. Treatment-resistant depressions. Psychopharmacology: The fourth generation of progress 1995: 1081-1097
10 Rush AJ, Trivedi MH, Wisniewski SR. et al Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. American Journal of Psychiatry 2006; 163 (11) 1905-1917
11 Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. Journal of Clinical Psychiatry 2006; 67 (09) 1412-1421
12 McAllister-Williams RH, Arango C, Blier P. et al The identification, assessment and management of difficult-to-treat depression: An international consensus statement. J Affect Disord 2020; 267: 264-282
13 Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. Journal of affective disorders 2012; 139 (02) 172-180
14 Selalmazidou AM, Bschor T. Depression: Niedrigschwellige Kardinalmaßnahmen als Basis jeder Behandlung. PSYCH up2date 2023; 17 (02) 117-130
15 Repple J, Opel N. Sport und körperliche Bewegung bei unipolarer Depression. Prävention, Therapie und neurobiologische Wirkmechanismen. Nervenarzt 2021; 92: 507-514
16 Haaf R, Machleid F, Köhler S.. Überblick über Digitale Gesundheitsanwendungen mit Fokus Depression. Nervenheilkunde 2023; 41: 430-437
17 Kaczmarczyk M, Otte C. Pharmakotherapie depressiver Störungen. PSYCH up2date 2022; 16 (03) 229-250
18 Stastka K. Psychotherapie bei Depression. Psychopraxis. Neuropraxis 2016; 19: 186-191
19 Brakemeier EL, Jacobi F.. Verhaltenstherapie in der Praxis. Weinheim: Beltz; 2017
20 Sinyor M, Schaffer A, Levitt A.. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review. Canadian Journal of Psychiatry 2010; 55 (03) 126-135
21 Hiemke C, Bergemann N, Clement HW. et al Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51 1–02 9-62
22 Debonnel G, Saint-André É, Hébert C. et al Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology 2007; 10 (01) 51-61
23 Adli M, Baethge A, Heinz N. et al Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European archives of psychiatry and clinical neuroscience 2005; 255: 387-400
24 Bschor T, Kern H, Henssler J. et al Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. The Journal of Clinical Psychiatry 2016; 79 (01) 20627
25 Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. The Canadian Journal of Psychiatry 2016; 61 (01) 29-43
26 Henssler J, Alexander D, Schwarzer G. et al Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022; 79 (04) 300-312
27 Strawbridge R, Carter B, Marwood L. et al Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. The British Journal of Psychiatry 2019; 214 (01) 42-51
28 Crossley NA, Bauer M.. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68 (06) 935-940
29 Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12 (23) 2985-2992
30 Nelson JC, Baumann P, Delucchi K. et al A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of affective disorders 2014; 168: 269-275
31 Osterland SL, Adli M, Saritas T. et al Acute effects of lithium augmentation on the kidney in geriatric compared with non-geriatric patients with treatment-resistant depression. Acta Psychiatrica Scandinavica 2023; 147 (03) 267-275
32 Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18 (02) 63-101
33 Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166 (09) 980-991
34 Bauer M, Heinz A, Whybrow P. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Molecular psychiatry 2002; 07 (02) 140-156
35 Köberle U. Augmentation mit Schilddrüsenhormonen. Behandlungsmanual therapieresistente Depression. Pharmakotherapie-somatische Therapieverfahren–Psychotherapie. Stuttgart: Kohlhammer; 2008
36 Caspar F.. Beziehungen und Probleme verstehen: Eine Einführung in die psychotherapeutische Plananalyse. Göttingen: Hogrefe; 2018
37 Hayes SC, Hofmann SG.. Process-based CBT: The science and core clinical competencies of cognitive behavioral therapy. New York: New Harbinger Publications; 2018
38 van Bronswijk S, Moopen N, Beijers L. et al Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychological medicine 2019; 49 (03) 366-379
39 Schramm E, Elsaesser M, Domschke K. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. The Lancet Psychiatry 2020; 07 (09) 801-812
40 Köhler SJ, Baumann N, Baghai TC. Differences between chronic and nonchronic depression: Systematic review and implications for treatment. Depression and Anxiety 2019; 36 (01) 18-30
41 McCullough Jr JP, Schramm E, Penberthy JK. CBASP as a distinctive treatment for persistent depressive disorder: distinctive features. London: Routledge; 2014
42 Guhn A, Köhler S J, Klein J. CBASP – eine evidenzbasierte und praxisorientierte Einführung. PSYCH up2date 2022; 16(4)
43 Brakemeier EL.. Cognitive Behavioral Analysis System of Psychotherapy (CBASP) vs. Behavioral Activation (BA) bei stationären Patienten mit persistierend depressiven und therapieresistenten Störungen: Wirksamkeit, Moderatoren und Mediatoren der Veränderung. https://psychologie.uni-greifswald.de/changepdd Stand: 1.6.2023
44 Buthut M, Haslacher D, Soekadar SR. Behandlung depressiver Störungen mittels nicht-invasiver Neuromodulation. Nervenheilkunde 2023; 41: 438-448
45 Group UER.Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. The Lancet 2003; 361 9360 799-808
46 Weiner RD, Reti IM. Key updates in the clinical application of electroconvulsive therapy. International Review of Psychiatry 2017; 29 (02) 54-62
47 Elias A, Phutane VH, Clarke S. et al Electroconvulsive therapy in the continuation and maintenance treatment of depression: Systematic review and meta-analyses. Australian & New Zealand Journal of Psychiatry 2018; 52 (05) 415-424
48 Sonmez AI, Camsari DD, Nadakumar AL. Accelerated TMS for Depression: A systematic review and meta-analysis. Psychiatry Res 2019; 273: 770-781
49 Huang YZ, Edwards MJ, Rounis E. et al Theta burst stimulation of the human motor cortex. Neuron 2005; 45 (02) 201-6
50 Cole EJ, Phillips AL, Bentzley BS. et al Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry 2022; 179 (02) 132-141
51 Reif-Leonhard C, Reif A, Baune B. et al Vagusnervstimulation bei schwer zu behandelnden Depressionen. Der Nervenarzt 2022; 93 (09) 921-930
52 Aaronson ST, Sears P, Ruvuna F. et al A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. American Journal of Psychiatry 2017; 174 (07) 640-648
53 Kisely SA, Li A, Warren N. et al A systematic review and meta-analysis of deep brain stimulation for depression. Depression and Anxiety 2018; 35: 468-480
54 Coenen VA, Bewernick BH, Kayser S. et al Superolateral medial forebrain bundle deep brain stimulation in major depression: A gateway trial. Neuropsychopharmacology 2019; 44 (07) 1224-1232
55 Dougherty D, Rezai A, Carpenter L. et al A randomized sham controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biological Psychiatry 2015; 78: 240-248
56 Holtzheimer PE, Husain MM, Lisanby SH. et al Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. The Lancet Psychiatry 2017; 04 (11) 839-849
57 Müller S, van Oosterhout A, Bervoets C. et al Concerns About Psychiatric Neurosurgery and How They Can Be Overcome: Recommendations for Responsible Research. Neuroethics 2022; 15: 6
58 Papakostas GI, Salloum NC, Hock RS. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. The Journal of Clinical Psychiatry 2020; 81 (04) 19r12889
59 Daly EJ, Trivedi MH, Janik A. et al Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76 (09) 893-903
60 Fedgchin M, Trivedi M, Daly EJ. et al Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology 2019; 22 (10) 616-630
61 Nichols DE. Chemistry and structure–activity relationships of psychedelics. Behavioral Neurobiology of Psychedelic Drugs 2018: 1-43
62 Becher, et al Psychedelika-gestützte Psychotherapie in der Behandlung depressiver Störungen. Ein Blick auf die Vergangenheit, den Stand der Forschung und die Zukunft. Nervenheilkunde 2023; 41: 450-458
63 Ko K, Knight G, Rucker JJ. et al Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Frontiers in psychiatry 2022: 13
64 Kupfer DJ. Management of Recurrent Depression. J ClinPsychiatry 1993; 54: 29-33